Flax Pond Capital LLC acquired a new position in shares of uniQure N.V. (NASDAQ:QURE – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 146,498 shares of the biotechnology company’s stock, valued at approximately $3,506,000. uniQure comprises about 2.6% of Flax Pond Capital LLC’s portfolio, making the stock its 14th biggest position.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Torren Management LLC bought a new position in shares of uniQure in the fourth quarter worth about $28,000. Jones Financial Companies Lllp lifted its position in shares of uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares in the last quarter. IFP Advisors Inc bought a new stake in shares of uniQure during the fourth quarter valued at approximately $48,000. Smartleaf Asset Management LLC bought a new stake in shares of uniQure during the fourth quarter valued at approximately $48,000. Finally, CIBC Private Wealth Group LLC acquired a new stake in shares of uniQure in the third quarter valued at approximately $50,000. Institutional investors and hedge funds own 78.83% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms recently weighed in on QURE. Royal Bank Of Canada boosted their price objective on shares of uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday. The Goldman Sachs Group increased their price objective on uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a research report on Thursday. Barclays raised uniQure from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $25.00 to $65.00 in a research note on Thursday. Wolfe Research began coverage on uniQure in a research report on Monday, February 23rd. They set a “peer perform” rating for the company. Finally, Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Twelve investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, uniQure presently has an average rating of “Moderate Buy” and an average target price of $58.92.
uniQure Price Performance
Shares of QURE opened at $46.29 on Friday. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure N.V. has a 1 year low of $8.73 and a 1 year high of $71.50. The stock has a market cap of $2.92 billion, a P/E ratio of -13.30 and a beta of 0.98. The stock’s 50-day moving average price is $24.74 and its two-hundred day moving average price is $22.20.
uniQure (NASDAQ:QURE – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. The company had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. On average, equities analysts predict that uniQure N.V. will post -3.64 earnings per share for the current year.
Key Headlines Impacting uniQure
Here are the key news stories impacting uniQure this week:
- Positive Sentiment: The FDA’s feedback now appears to support a near-term biologics license application for AMT-130, increasing the odds of accelerated approval for Huntington’s disease and boosting sentiment around uniQure’s lead program. Reuters
- Positive Sentiment: Barclays upgraded uniQure and raised its price target to $65 from $25, reflecting a more constructive view of the company after the FDA development. Benzinga
- Positive Sentiment: uniQure also announced preliminary AMT-260 data in refractory mesial temporal lobe epilepsy, saying the treatment was generally well tolerated with no serious adverse events so far and early signs of biological activity. GlobeNewswire
- Neutral Sentiment: Insider selling by a director and an executive has drawn attention, but the trades were disclosed and at least one was made under a pre-arranged 10b5-1 plan, so they are less likely to be interpreted as a fundamental warning sign.
- Neutral Sentiment: Several articles argue the stock may still be undervalued after the FDA update, but those calls mostly reflect optimism already fueled by the regulatory news rather than a new company-specific catalyst. Yahoo Finance
Insider Activity
In other uniQure news, insider Kylie O’keefe sold 15,936 shares of the stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total value of $431,228.16. Following the sale, the insider directly owned 108,864 shares in the company, valued at approximately $2,945,859.84. This trade represents a 12.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Madhavan Balachandran sold 10,000 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $27.85, for a total transaction of $278,500.00. Following the completion of the sale, the director owned 43,254 shares in the company, valued at approximately $1,204,623.90. This trade represents a 18.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 101,054 shares of company stock valued at $2,655,791. 4.65% of the stock is currently owned by company insiders.
About uniQure
uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.
Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.
Featured Articles
- Five stocks we like better than uniQure
- Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for uniQure N.V. (NASDAQ:QURE – Free Report).
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
